Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
ORIGINAL ARTICLES
Recommendations for the Management of Neuro-Behçet's Disease by the Japanese National Research Committee for Behçet's Disease
Shunsei HirohataHirotoshi KikuchiTetsuji SawadaMasato OkadaMitsuhiro TakenoMasataka KuwanaIzumi KawachiHideki MochizukiSusumu KusunokiYoshiaki Ishigatsubo
Author information
JOURNALS OPEN ACCESS
Supplementary material

2020 Volume 59 Issue 19 Pages 2359-2367

Details
Abstract

Objective Brain parenchymal involvement in Behçet's disease (BD) (neuro-Behçet's disease, NB) can be classified into acute type (ANB) and chronic progressive type (CPNB) based on differences in the clinical course and responses to corticosteroid treatment. The present study developed evidence-based recommendations for the management of NB.

Methods The task force of the research subcommittee consisted of seven board-certified rheumatologists (one was also a board-certified neurologist) and three board-certified neurologists. First, several clinical questions (CQs) were established. A systematic literature search was performed by The Japan Medical Library Association in order to develop recommendations. The final recommendations for each CQ developed from three blind Delphi rounds, for which the rate of agreement scores [range 1 (strongly disagree)-5(strongly agree)] was determined through voting by the task force.

Results A flow chart of the algorithm was established for the management of ANB and CPNB. Thirteen recommendations were developed for NB (general 1, ANB 7, CPNB 5). The strength of each recommendation was established based on the evidence level as well as the rate of agreement.

Conclusion The recommendations generated in this study are based on the results of uncontrolled evidence from open trials, retrospective cohort studies and expert opinions, due to the lack of randomized clinical trials. Nevertheless, these recommendations can be used for international studies, although verification by further properly designed controlled clinical trials is required.

Information related to the author
© 2020 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top